Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Alteration of DNA Methylation in Gastric Cancer with Chemotherapy

  • Choi, Su Jin (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University) ;
  • Jung, Seok Won (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University) ;
  • Huh, Sora (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University) ;
  • Chung, Yoon-Seok (Division of Viral Diseases Center for Laboratory Control of Infectious Disease, Korea Centers for Disease Control and Prevention) ;
  • Cho, Hyosun (College of Pharmacy and Innovative Drug Center, Duksung Women's University) ;
  • Kang, Hyojeung (College of Pharmacy, Cancer Research Institute, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University)
  • Received : 2017.04.14
  • Accepted : 2017.06.11
  • Published : 2017.08.28
Download PDF
⟨ Previous Next ⟩

Abstract

Epigenetic alterations such as DNA methylation, histone acetylation, and chromatin remodeling can control gene expression by regulating gene transcription. DNA methylation is one of the frequent epigenetic events that play important roles in cancer development. Cancer cells can gain significant resistance to anticancer drugs and escape programmed cell death through major epigenetic changes, including DNA methylation. To date, several research groups have identified instances of both (i) hypermethylation of tumor suppressor genes, and (ii) global hypomethylation of oncogenes. These changes in DNA methylation status could be used as biomarkers for the diagnosis and prognosis of cancer patients undergoing chemotherapies or other clinical therapies. Herein, we describe genes for which methylation is dependent upon anticancer drug resistance in patients with gastric cancer; we then suggest a significant epigenetic target to focus on for overcoming anticancer drug resistance.

Keywords

References

  1. Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat. Rev. Clin. Oncol. 2: S4. https://doi.org/10.1038/ncponc0354
  2. Das PM, Singal R. 2004. DNA methylation and cancer. J. Clin. Oncol. 22: 4632-4642. https://doi.org/10.1200/jco.2004.22.14_suppl.4632
  3. Fu D-G. 2015. Epigenetic alterations in gastric cancer (Review). Mol. Med. Rep. 12: 3223-3230. https://doi.org/10.3892/mmr.2015.3816
  4. Kang C, Song J-J, Lee J, Kim MY. 2014. Epigenetics: an emerging player in gastric cancer. World J. Gastroenterol. 20: 6433-6447. https://doi.org/10.3748/wjg.v20.i21.6433
  5. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. 2004. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol. 164: 689-699. https://doi.org/10.1016/S0002-9440(10)63156-2
  6. Li L, Li C, Mao H, Du Z, Chan WY, Murray P, et al. 2016. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci. Rep. 6: 26591. https://doi.org/10.1038/srep26591
  7. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13: 714-726. https://doi.org/10.1038/nrc3599
  8. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. 2014. Drug resistance in cancer: an overview. Cancers 6: 1769-1792. https://doi.org/10.3390/cancers6031769
  9. Chen C-C, Lee K-D, Pai M-Y, Chu P-Y, Hsu C-C, Chiu C-C, et al. 2015. Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. Cancer Cell Int. 15: 98. https://doi.org/10.1186/s12935-015-0248-3
  10. Carcas LP. 2014. Gastric cancer review. J. Carcinog. 13: 14. https://doi.org/10.4103/1477-3163.146506
  11. Guo X, Xia J, Yan J. 2015. Promoter methylated microRNAs: potential therapeutic targets in gastric cancer (Review). Mol. Med. Rep. 11: 759-765. https://doi.org/10.3892/mmr.2014.2780
  12. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, et al. 2013. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 62: 22-33. https://doi.org/10.1136/gutjnl-2011-301113
  13. Kang KA, Piao MJ, Kim KC, Kang HK, Chang WY, Park IC, et al. 2014. Epigenetic modification of Nrf2 in 5-fluorouracilresistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis. 5: e1183. https://doi.org/10.1038/cddis.2014.149
  14. Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, et al. 2007. Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J. Gastroenterol. 42: 866-873. https://doi.org/10.1007/s00535-007-2113-1
  15. Florea A-M, Busselberg D. 2011. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3: 1351-1371. https://doi.org/10.3390/cancers3011351
  16. Stewart DJ. 2007. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63: 12-31. https://doi.org/10.1016/j.critrevonc.2007.02.001
  17. Napieralski R, Ott K, Kremer M, Becker K, Boulesteix A-L, Lordick F, et al. 2007. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin. Cancer Res. 13: 5095-5102. https://doi.org/10.1158/1078-0432.CCR-07-0241
  18. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, et al. 2008. Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int. J. Cancer 122: 603-608. https://doi.org/10.1002/ijc.23143
  19. Kwon OH, Park JL, Baek SJ, Noh SM, Song KS, Kim SY, et al. 2013. Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells. Cancer Sci. 104: 391-397. https://doi.org/10.1111/cas.12076
  20. Hu X, Sui X, Li L, Huang X, Rong R, Su X, et al. 2013. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J. Pathol. 229: 62-73. https://doi.org/10.1002/path.4093
  21. Maeda O, Ando T, Ohmiya N, Ishiguro K, Watanabe O, Miyahara R, et al. 2014. Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol. Rep. 31: 1883-1890. https://doi.org/10.3892/or.2014.3014
  22. Xia LL, Tang YB, Song FF, Xu L, Ji P, Wang SJ, et al. 2016. DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorouracil by up-regulating MDR1 expression epigenetically. Oncotarget 7: 68623-68637. https://doi.org/10.18632/oncotarget.11864
  23. Zhang Y, Ye WY, Wang JQ, Wang SJ, Ji P, Zhou GY, et al. 2013. dCTP Pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas. Eur. J. Histochem. 57: e29. https://doi.org/10.4081/ejh.2013.e29
  24. Sun J, Du N, Li J, Zhou J, Tao G, Sun S, et al. 2016. Transcription factor AP2$\varepsilon$. Technol. Cancer Res. Treat. 15: 285-295. https://doi.org/10.1177/1533034615577028
  25. Zhang Y, Qu X, Jing W, Hu X, Yang X, Hou K, et al. 2009. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Anti cancer Drugs 20: 208-214. https://doi.org/10.1097/CAD.0b013e328322fbaa
  26. Shen J, Wei J, Wang H, Yang Y, Yue G, Wang L, et al. 2013. SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen. PLoS One 8: e75564. https://doi.org/10.1371/journal.pone.0075564
  27. Zhou W, Wang J, Man WY, Zhang QW, Xu WG. 2015. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Asian Pac. J. Cancer Prev. 16: 2425-2430. https://doi.org/10.7314/APJCP.2015.16.6.2425
  28. Subhash VV, Tan SH, Tan WL, Yeo MS, Xie C, Wong FY, et al. 2015. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer 15: 550. https://doi.org/10.1186/s12885-015-1550-0
  29. Yeh CM, Chang LY, Lin SH, Chou JL, Hsieh HY, Zeng LH, et al. 2016. Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer. Sci. Rep. 6: 31690. https://doi.org/10.1038/srep31690
  30. Jeon MS, Song SH, Yun J, Kang JY, Kim HP, Han SW, et al. 2016. Aberrant epigenetic modifications of LPHN2 function as a potential cisplatin-specific biomarker for human gastrointestinal cancer. Cancer Res. Treat. 48: 676-686. https://doi.org/10.4143/crt.2015.153
  31. Su C, Li J, Cao Y, Xiao L, Shi C. 2017. Long noncoding RNA HOTAIR promotes cisplatin resistance in gastric cancer through promoting WIF-1 promoter methylation. Int. J. Clin. Exp. Med. 10: 2717-2726.
  32. Sugita H, Iida S, Inokuchi M, Kato K, Ishiguro M, Ishikawa T, et al. 2011. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol. Rep. 25: 513.
  33. Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M. 2013. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Mol. Cancer Res. 11: 1362-1374. https://doi.org/10.1158/1541-7786.MCR-13-0091
  34. Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y, et al. 2014. Methylation of miR-129-5p CpG island modulates multidrug resistance in gastric cancer by targeting ABC transporters. Oncotarget 5: 11552-11563. https://doi.org/10.18632/oncotarget.2594
  35. Yu Y, Yan W, Liu X, Jia Y, Cao B, Yu Y, et al. 2014. DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. Am. J. Cancer Res. 4: 710.
  36. Gou WF, Yang XF, Shen DF, Zhao S, Liu YP, Sun HZ, et al. 2015. The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy. Oncotarget 6: 19841-19867. https://doi.org/10.18632/oncotarget.3734
  37. Mi H, Muruganujan A, Thomas PD. 2013. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 41: D377-D386.
  38. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14: 128. https://doi.org/10.1186/1471-2105-14-128
  39. Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53: 615-627. https://doi.org/10.1146/annurev.med.53.082901.103929

Cited by

  1. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival vol.144, pp.9, 2018, https://doi.org/10.1007/s00432-018-2701-x
  2. DNA methylation in human diseases vol.5, pp.1, 2017, https://doi.org/10.1016/j.gendis.2018.01.002
  3. Magnesium-dependent Phosphatase (MDP) 1 is a Potential Suppressor of Gastric Cancer vol.19, pp.10, 2017, https://doi.org/10.2174/1568009619666190620112546
  4. Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status vol.13, pp.None, 2019, https://doi.org/10.3389/fnins.2019.00237
  5. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation vol.38, pp.1, 2017, https://doi.org/10.1186/s13046-019-1193-0
  6. Significant function and research progress of biomarkers in gastric cancer vol.19, pp.1, 2017, https://doi.org/10.3892/ol.2019.11078
  7. An Analysis Regarding the Association Between the ISLR Gene and Gastric Carcinogenesis vol.11, pp.None, 2017, https://doi.org/10.3389/fgene.2020.00620
  8. Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer vol.11, pp.None, 2020, https://doi.org/10.3389/fphar.2020.616251
  9. DNA Methyltransferase and its Clinical Applications vol.512, pp.None, 2017, https://doi.org/10.1088/1755-1315/512/1/012082
  10. Association between the methylation of the STAT1 and SOCS3 in peripheral blood and gastric cancer vol.35, pp.8, 2017, https://doi.org/10.1111/jgh.15021
  11. A methylation‐based mRNA signature predicts survival in patients with gastric cancer vol.20, pp.None, 2017, https://doi.org/10.1186/s12935-020-01374-w
  12. Overview of Epstein–Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options vol.21, pp.24, 2017, https://doi.org/10.3390/ijms21249400
  13. Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis vol.32, pp.9, 2017, https://doi.org/10.1097/cad.0000000000001087
  14. Neuronal pentraxin II (NPTX2) hypermethylation promotes cell proliferation but inhibits cell cycle arrest and apoptosis in gastric cancer cells by suppressing the p53 signaling pathway vol.12, pp.1, 2017, https://doi.org/10.1080/21655979.2021.1915658
  15. RORα and REV-ERBα are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer vol.20, pp.None, 2017, https://doi.org/10.1177/15330338211039670
  16. Using lncRNA Sequencing to Reveal a Putative lncRNA-mRNA Correlation Network and the Potential Role of PCBP1-AS1 in the Pathogenesis of Cervical Cancer vol.11, pp.None, 2017, https://doi.org/10.3389/fonc.2021.634732
  17. Rapid Detection of DNA Methylation with a Novel Real-Time Fluorescence Recombinase-Aided Amplification Assay vol.17, pp.7, 2017, https://doi.org/10.1166/jbn.2021.3111
  18. Cisplatin Resistance in Epstein-Barr-Virus-Associated Gastric Carcinoma Acquired through ATM Methylation vol.13, pp.17, 2017, https://doi.org/10.3390/cancers13174252
  19. The role of non-coding RNAs in chemotherapy for gastrointestinal cancers vol.26, pp.None, 2017, https://doi.org/10.1016/j.omtn.2021.10.004
  20. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors vol.13, pp.1, 2021, https://doi.org/10.1186/s13148-021-01045-1
  21. Is there a relationship between neural EGFL like 1 (NELL1) promoter hypermethylation and prognosis of gastric cancer? vol.158, pp.None, 2017, https://doi.org/10.1016/j.mehy.2021.110723